Sandoz Canada Completes Sale of Sterile Injectable Medicine Manufacturing Plant
- Sandoz Canada has signed an agreement with Delpharm, a contract development and manufacturing organization (CDMO), to sell the Boucherville plant. This agreement met the closing conditions as of February 28, 2022.
- As part of the transaction, Delpharm and Sandoz Canada signed a long-term supply and manufacturing agreement. This ensures that Sandoz Canada will maintain local production of all its Quebec-Canadian origin injectable medicines.
- Boucherville plant employees will keep their jobs under the new ownership at substantially similar conditions.
Boucherville, QC, March 1, 2022 – Sandoz Canada announced today the completion of the sale of its Boucherville, Quebec, manufacturing plant to Delpharm. This plant is the largest sterile injectable production facility in Canada and provides strategic and potentially lifesaving medicines to the Canadian and US healthcare systems, mostly hospitals.
While all Sandoz Canada injectable products will be manufactured by Delpharm with the same high-quality formulations as before, Sandoz Canada remains the owner of the marketing authorizations and intellectual property and will continue to have commercial responsibility for all its products. Delpharm intends to invest in the site and pursue business development opportunities to enable its growth.
“We’re pleased to be partnering with a reliable CDMO like Delpharm,” said Michel Robidoux, President and General Manager of Sandoz Canada. “As part of this acquisition, we’ve signed a long-term agreement for Delpharm to provide Sandoz Canada with continuous supply of medicines manufactured in Boucherville, as well as an agreement maintaining jobs. Our injectables will continue to be manufactured in Quebec by the same expert team, and Sandoz Canada will continue to support patients, hospitals, physicians and pharmacists with the same vast portfolio of biosimilar and generic medicines, including these injectables.”
This media update contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “may,” “could,” “would,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this media update, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this media update will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Neither can there be any guarantee that, if approved, such generic or biosimilar products will be approved for all indications included in the reference product’s label. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; the particular prescribing preferences of physicians and patients; competition in general, including potential approval of additional generic or biosimilar versions of such products; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; litigation outcomes, including intellectual property disputes or other legal efforts to prevent or limit Sandoz from selling its products; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this media update as of this date and does not undertake any obligation to update any forward-looking statements contained in this media update as a result of new information, future events or otherwise.
Sandoz International GmbH is a global leader in generic pharmaceuticals and biosimilars and a division of the Swiss multinational Novartis.
Sandoz Canada is a pioneer, a leader and trusted supplier of quality generics and biosimilars with over 65 million prescriptions per year, based on decades of global experience and capabilities in the development, manufacturing and commercialization of its products. Sandoz launched the first biosimilar in Europe in 2006 and in the Canadian market in 2009.
# # #
Sandoz Canada Communications